RhumbLine Advisers’s Veracyte VCYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.1M | Sell |
188,952
-24,282
| -11% | -$1.02M | 0.01% | 1044 |
|
|
2026
Q1 | $6.87M | Buy |
213,234
+2,123
| +1% | +$78.6K | 0.01% | 1238 |
|
|
2025
Q4 | $8.89M | Sell |
211,111
-11,091
| -5% | -$447K | 0.01% | 1115 |
|
|
2025
Q3 | $7.63M | Buy |
222,202
+102,653
| +86% | +$2.95M | 0.01% | 1216 |
|
|
2025
Q2 | $3.23M | Sell |
119,549
-905
| -0.8% | -$26.2K | ﹤0.01% | 1632 |
|
|
2025
Q1 | $3.57M | Sell |
120,454
-2,870
| -2% | -$109K | ﹤0.01% | 1522 |
|
|
2024
Q4 | $4.88M | Buy |
123,324
+675
| +0.6% | +$25.6K | ﹤0.01% | 1432 |
|
|
2024
Q3 | $4.17M | Sell |
122,649
-6,125
| -5% | -$172K | ﹤0.01% | 1523 |
|
|
2024
Q2 | $2.79M | Buy |
128,774
+8,096
| +7% | +$170K | ﹤0.01% | 1711 |
|
|
2024
Q1 | $2.67M | Buy |
120,678
+2,746
| +2% | +$67K | ﹤0.01% | 1758 |
|
|
2023
Q4 | $3.24M | Sell |
117,932
-447
| -0.4% | -$10.8K | ﹤0.01% | 1659 |
|
|
2023
Q3 | $2.64M | Buy |
118,379
+1,833
| +2% | +$47.1K | ﹤0.01% | 1721 |
|
|
2023
Q2 | $2.97M | Sell |
116,546
-319
| -0.3% | -$7.73K | ﹤0.01% | 1691 |
|
|
2023
Q1 | $2.61M | Buy |
116,865
+1,901
| +2% | +$45.9K | ﹤0.01% | 1672 |
|
|
2022
Q4 | $2.73M | Buy |
114,964
+3,508
| +3% | +$81.5K | ﹤0.01% | 1622 |
|
|
2022
Q3 | $1.85M | Buy |
111,456
+6,149
| +6% | +$138K | ﹤0.01% | 1809 |
|
|
2022
Q2 | $2.1M | Buy |
105,307
+16,336
| +18% | +$330K | ﹤0.01% | 1742 |
|
|
2022
Q1 | $2.45M | Sell |
88,971
-7,510
| -8% | -$215K | ﹤0.01% | 1706 |
|
|
2021
Q4 | $3.98M | Sell |
96,481
-1,149
| -1% | -$50.8K | ﹤0.01% | 1501 |
|
|
2021
Q3 | $4.54M | Buy |
97,630
+1,958
| +2% | +$85.4K | 0.01% | 1412 |
|
|
2021
Q2 | $3.83M | Buy |
95,672
+25,988
| +37% | +$1.11M | 0.01% | 1588 |
|
|
2021
Q1 | $3.75M | Sell |
69,684
-453
| -0.6% | -$26.1K | 0.01% | 1571 |
|
|
2020
Q4 | $3.43M | Buy |
70,137
+4,329
| +7% | +$201K | ﹤0.01% | 1568 |
|
|
2020
Q3 | $2.14M | Sell |
65,808
-6,393
| -9% | -$203K | ﹤0.01% | 1645 |
|
|
2020
Q2 | $1.87M | Buy |
72,201
+7,586
| +12% | +$189K | ﹤0.01% | 1770 |
|
|
2020
Q1 | $1.57M | Buy |
64,615
+1,137
| +2% | +$28.6K | ﹤0.01% | 1672 |
|
|
2019
Q4 | $1.77M | Buy |
63,478
+4,351
| +7% | +$113K | ﹤0.01% | 1841 |
|
|
2019
Q3 | $1.42M | Buy |
59,127
+343
| +0.6% | +$9.12K | ﹤0.01% | 1887 |
|
|
2019
Q2 | $1.68M | Buy |
58,784
+23,093
| +65% | +$577K | ﹤0.01% | 1842 |
|
|
2019
Q1 | $893K | Buy |
35,691
+182
| +0.5% | +$3.48K | ﹤0.01% | 2097 |
|
|
2018
Q4 | $447K | Buy |
35,509
+13,667
| +63% | +$162K | ﹤0.01% | 2347 |
|
|
2018
Q3 | $209K | Sell |
21,842
-375
| -2% | -$4.14K | ﹤0.01% | 2709 |
|
|
2018
Q2 | $208K | Buy |
22,217
+1,755
| +9% | +$12.3K | ﹤0.01% | 2717 |
|
|
2018
Q1 | $114K | Buy |
20,462
+95
| +0.5% | +$588 | ﹤0.01% | 2724 |
|
|
2017
Q4 | $133K | Sell |
20,367
-4,752
| -19% | -$35.3K | ﹤0.01% | 2732 |
|
|
2017
Q3 | $220K | Buy |
25,119
+370
| +1% | +$3.01K | ﹤0.01% | 2685 |
|
|
2017
Q2 | $206K | Buy |
24,749
+8,702
| +54% | +$71K | ﹤0.01% | 2744 |
|
|
2017
Q1 | $147K | Buy |
16,047
+1,799
| +13% | +$14.7K | ﹤0.01% | 2724 |
|
|
2016
Q4 | $110K | Buy |
14,248
+1,105
| +8% | +$8.27K | ﹤0.01% | 2783 |
|
|
2016
Q3 | $100K | Buy |
13,143
+140
| +1% | +$792 | ﹤0.01% | 2806 |
|
|
2016
Q2 | $65K | Buy |
13,003
+450
| +4% | +$2.41K | ﹤0.01% | 2955 |
|
|
2016
Q1 | $68K | Hold |
12,553
| – | – | ﹤0.01% | 2941 |
|
|
2015
Q4 | $90K | Buy |
12,553
+1,265
| +11% | +$8.52K | ﹤0.01% | 2968 |
|
|
2015
Q3 | $53K | Buy |
11,288
+443
| +4% | +$4.22K | ﹤0.01% | 2991 |
|
|
2015
Q2 | $121K | Buy |
+10,845
| New | +$107K | ﹤0.01% | 2989 |
|
Other funds holding VCYT
AIM
RhumbLine Advisers's VCYT Position: Q2 2026 in Review
RhumbLine Advisers reduced its Veracyte (VCYT) stake by 11% in Q2 2026, selling an estimated $1.02M and leaving 188,952 shares worth $11.1M. The position accounts for 0.01% of the portfolio, ranked #1044.
RhumbLine Advisers first reported a position in VCYT in Q2 2015 and has held it in 45 quarters since. 369 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.
- RhumbLine Advisers held 188,952 shares of Veracyte worth $11.1M as of Q2 2026.
- RhumbLine Advisers sold 24,282 Veracyte shares in Q2 2026, an estimated $1.02M.
- Veracyte made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1044 holding.
- RhumbLine Advisers first reported a position in Veracyte in Q2 2015 and has held it in 45 quarters since.
- 369 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.